Law Offices of Howard G. Smith announces an investigation on behalf of Globus Medical, Inc. (“Globus Medical” or the “Company”) (NYSE: GMED) investors concerning the Company’s possible violations of federal securities laws.

On August 13, 2024, the FDA published a warning letter to Globus Medical regarding an inspection of the Company’s Class II Excelsius GPS (EGPS) surgical robot, stating that the inspection revealed that “these devices are adulterated” and are not in conformity quality system regulation requirements.

On this news, Globus Medical’s stock price fell $5.73, or 7.8%, to close at $67.32 per share on August 13, 2024, thereby injuring investors.

If you purchased Globus Medical securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847 or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240815996036/en/